Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
NORMIFLO (ardeparin sodium) is an injectable low-molecular-weight heparin (LMWH) in pre-launch development by Pfizer. The drug is indicated for thromboembolism prevention and treatment through subcutaneous injection. Ardeparin works by inhibiting coagulation cascade factors, reducing clot formation in high-risk patient populations.
Pre-Launch
Pre-launch stage indicates active commercial buildout with recruitment across sales, marketing, and medical affairs functions.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
NORMIFLO pre-launch phase offers entry or transition opportunities in Pfizer's injectable anticoagulant franchise, particularly for professionals with LMWH market experience or hospital/specialty pharmacy networks. However, the mature and declining LMWH market, coupled with DOAC displacement, signals limited long-term commercial upside and potential career risk if launch disappoints.
Brand Manager
Worked on NORMIFLO at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.